This 2015 commentary discusses a study involving 1,023 hypogonadal men undergoing testosterone therapy (TST) across three registries with a median follow-up of five years. The study found prostate cancer incidences of 2.3% and 1.5% in two cohorts, with no cases in the third. These rates are lower than those reported
